Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 10, 2014, Pages 1529-1537

  Kodjikian, Laurent ^a,b,c   Decullier, Evelyne ^b,d,e   Souied, Eric H ^f,g   Girmens, Jean François ^h   Durand, Emilie E ^d   Chapuis, François R ^b,d,e   Huot, Laure ^b,d,e  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e UNIVERSITÉ DE LYON   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Bevacizumab; Meta analysis; Neovascular age related macular degeneration; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; EMBASE; ENDOPHTHALMITIS; EYE DISEASE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART INFARCTION; HUMAN; INFECTION; INTRAOCULAR HEMORRHAGE; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; META ANALYSIS; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; RISK; SERIOUS NON OCULAR HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84920951847     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2764-6     Document Type: Review

References (15)

1. Stein JD, Hanrahan BW, Comer GM, Sloan FA (2013) Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. Am J Ophthalmol 155(4):688–696. doi:10.1016/j.ajo.2012.10.003, 696 e681-682
2. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908. doi:10.1056/NEJMoa1102673
3. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399–1411. doi:10.1016/j.ophtha.2012.04.015
4. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G (2013) Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority randomized trial. Ophthalmology 120(11):2300–2309. doi:10.1016/j.ophtha.2013.06.020
5. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schonherr U, Haas A, Ansari-Shahrezaei S, Binder S (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97(3):266–271. doi:10.1136/bjophthalmol-2012-302391
6. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7(8):e42701. doi:10.1371/journal.pone.0042701
7. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/
8. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557
10. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 59(3):191–196. doi:10.4103/0301-4738.81023
11. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011) Comparing ranibizumab with bevacizumab. Ophthalmology 118(3):600–600. doi:10.1016/j.ophtha.2010.10.027, e602
12. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 24(11):1708–1715. doi:10.1038/eye.2010.147
13. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonca LS, Fonseca SL, Goncalves R, Goncalves C, Falcao-Reis FM, Soares R (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90(1):e25–e30. doi:10.1111/j.1755-3768.2011.02240.x
14. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF (2013) Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 97(4):454–459. doi:10.1136/bjophthalmol-2012-302451
15. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113(11):2002.e2001–2012. doi:10.1016/j.ophtha.2006.05.070